Profile data is unavailable for this security.
About the company
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company's advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first LockBody product candidate, LB101, is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody used in solid tumors. Its other programs consist of earlier-stage preclinical assets, including ORX750, an orally administered, selective Orexin Receptor-2 (OX2R) agonist for the treatment of narcolepsy (NT1) with potential expansion into other sleep disorders, and MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH).
- Revenue in USD (TTM)6.85m
- Net income in USD-151.09m
- Incorporated2020
- Employees76.00
- LocationCentessa Pharmaceuticals PLC3Rd Floor, 1 Ashley RoadALTRINCHAM WA14 2DTUnited KingdomGBR
- Websitehttps://www.centessa.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cassava Sciences Inc | 0.00 | -97.22m | 954.00m | 29.00 | -- | 6.78 | -- | -- | -2.32 | -2.32 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -50.31 | -30.74 | -53.23 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Innoviva Inc | 310.46m | 179.72m | 960.91m | 112.00 | 6.85 | 1.44 | 4.46 | 3.10 | 2.24 | 2.24 | 3.96 | 10.66 | 0.2509 | 0.8825 | 4.19 | 2,771,991.00 | 14.52 | 26.24 | 15.62 | 28.53 | 86.27 | -- | 57.89 | 76.84 | 7.96 | -- | 0.398 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Tyra Biosciences Inc | 0.00 | -69.13m | 973.27m | 49.00 | -- | 3.90 | -- | -- | -1.62 | -1.62 | 0.00 | 4.75 | 0.00 | -- | -- | 0.00 | -28.10 | -- | -29.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -71.58m | 980.33m | 46.00 | -- | 3.53 | -- | -- | -2.18 | -2.18 | 0.00 | 5.95 | 0.00 | -- | -- | 0.00 | -40.31 | -42.26 | -44.80 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Liquidia Corp | 17.49m | -78.50m | 986.84m | 136.00 | -- | 18.84 | -- | 56.43 | -1.21 | -1.21 | 0.2691 | 0.6891 | 0.1413 | -- | 3.85 | 128,588.20 | -63.43 | -55.02 | -71.31 | -62.69 | 83.49 | 82.18 | -448.89 | -474.59 | -- | -26.14 | 0.4942 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Arcutis Biotherapeutics Inc | 59.61m | -262.14m | 988.53m | 296.00 | -- | 9.39 | -- | 16.58 | -3.90 | -3.90 | 0.8602 | 0.9161 | 0.1508 | 0.483 | 3.48 | 201,371.60 | -66.31 | -65.64 | -74.24 | -71.72 | 91.63 | -- | -439.79 | -1,513.03 | 6.80 | -8.11 | 0.6947 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Silence Therapeutics plc | 35.14m | -53.40m | 990.50m | 116.00 | -- | 37.03 | -- | 28.19 | -0.4907 | -0.4907 | 0.3222 | 0.216 | 0.2527 | -- | 94.73 | 302,915.70 | -38.40 | -43.18 | -47.88 | -53.35 | 54.24 | -- | -151.98 | -422.12 | -- | -15.11 | 0.0155 | -- | 40.97 | 305.31 | -2.74 | -- | 149.02 | -- |
| Petro Usa Inc | 0.00 | -33.38k | 1.00bn | -- | -- | -- | -- | -- | -0.0002 | -0.0002 | 0.00 | -0.0008 | 0.00 | -- | -- | -- | -19,074.29 | -192,120.00 | -- | -- | -- | -- | -- | -- | -- | -118.21 | -- | -- | -- | -- | -81.58 | -- | -- | -- |
| Eyepoint Pharmaceuticals Inc | 46.02m | -70.80m | 1.04bn | 121.00 | -- | 3.67 | -- | 22.57 | -1.84 | -1.84 | 1.18 | 5.43 | 0.1719 | 1.36 | 5.64 | 380,314.10 | -26.44 | -40.44 | -32.35 | -47.79 | 89.93 | 83.45 | -153.84 | -186.23 | 5.39 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Centessa Pharmaceuticals PLC - ADR | 6.85m | -151.09m | 1.08bn | 76.00 | -- | 3.99 | -- | 157.05 | -1.57 | -1.57 | 0.0713 | 2.39 | 0.017 | -- | 0.2081 | 90,171.05 | -37.56 | -- | -41.57 | -- | -- | -- | -2,204.66 | -- | -- | -- | 0.2427 | -- | -- | -- | 30.12 | -- | -- | -- |
| AbCellera Biologics Inc | 38.03m | -146.40m | 1.13bn | 586.00 | -- | 0.9717 | -- | 29.64 | -0.5062 | -0.5062 | 0.1315 | 3.96 | 0.0251 | -- | 1.10 | 64,890.79 | -9.67 | 6.08 | -10.49 | 6.67 | -- | -- | -384.99 | 24.69 | 7.32 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Prothena Corporation PLC | 91.37m | -147.03m | 1.18bn | 173.00 | -- | 2.11 | -- | 12.96 | -2.80 | -2.80 | 1.68 | 10.46 | 0.1256 | -- | -- | 528,150.30 | -20.22 | -14.20 | -21.82 | -15.11 | -- | -- | -160.92 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| MannKind Corp | 198.96m | -11.94m | 1.19bn | 414.00 | -- | -- | -- | 5.96 | -0.0464 | -0.0464 | 0.7087 | -0.9116 | 0.5165 | 2.50 | 12.55 | 480,584.50 | -3.10 | -26.07 | -3.99 | -37.80 | 68.45 | 59.68 | -6.00 | -57.61 | 3.31 | 0.5023 | 1.90 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Cullinan Therapeutics Inc | 0.00 | -153.16m | 1.19bn | 85.00 | -- | 2.61 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
Data as of May 02 2024. Currency figures normalised to Centessa Pharmaceuticals PLC's reporting currency: US Dollar USD
30.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Dec 2023 | 8.77m | 8.99% |
| EcoR1 Capital, LLCas of 31 Dec 2023 | 5.62m | 5.76% |
| Adage Capital Management LPas of 31 Dec 2023 | 2.90m | 2.97% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.79m | 2.86% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 2.54m | 2.60% |
| Octagon Capital Advisors LPas of 31 Dec 2023 | 2.06m | 2.11% |
| Point72 Asset Management LPas of 31 Dec 2023 | 1.84m | 1.89% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.21m | 1.24% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 1.12m | 1.14% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 1.01m | 1.04% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
